AVITA Medical, Inc. (RCEL): Price and Financial Metrics


AVITA Medical, Inc. (RCEL): $6.52

-0.18 (-2.69%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

RCEL POWR Grades

  • Sentiment is the dimension where RCEL ranks best; there it ranks ahead of 99.34% of US stocks.
  • RCEL's strongest trending metric is Quality; it's been moving up over the last 179 days.
  • RCEL's current lowest rank is in the Momentum metric (where it is better than 10.51% of US stocks).

RCEL Stock Summary

  • For RCEL, its debt to operating expenses ratio is greater than that reported by only 4.85% of US equities we're observing.
  • RCEL's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of merely 8.96% of US stocks.
  • With a year-over-year growth in debt of -63.41%, AVITA MEDICAL INC's debt growth rate surpasses just 3.85% of about US stocks.
  • Stocks that are quantitatively similar to RCEL, based on their financial statements, market capitalization, and price volatility, are DDD, ANIK, VBIV, WEAV, and FORG.
  • Visit RCEL's SEC page to see the company's official filings. To visit the company's web site, go to www.avitamedical.com.

RCEL Valuation Summary

  • In comparison to the median Healthcare stock, RCEL's EV/EBIT ratio is 155.81% lower, now standing at -4.8.
  • Over the past 38 months, RCEL's EV/EBIT ratio has gone up 21.8.

Below are key valuation metrics over time for RCEL.

Stock Date P/S P/B P/E EV/EBIT
RCEL 2022-11-25 4.9 1.9 -5.6 -4.8
RCEL 2022-11-23 5.3 2.0 -6.0 -5.3
RCEL 2022-11-22 5.2 2.0 -6.0 -5.3
RCEL 2022-11-21 5.2 2.0 -6.0 -5.3
RCEL 2022-11-18 5.4 2.1 -6.2 -5.4
RCEL 2022-11-17 5.2 2.0 -6.0 -5.2

RCEL's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • RCEL has a Quality Grade of D, ranking ahead of 9.85% of graded US stocks.
  • RCEL's asset turnover comes in at 0.314 -- ranking 128th of 186 Medical Equipment stocks.
  • 500 - Internal server error

The table below shows RCEL's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.314 0.810 -5.438
2020-12-31 0.239 0.845 -0.901
2020-06-30 0.335 0.837 -3.514
2019-06-30 0.292 1.195 -1.429
2019-06-30 0.550 1.103 -1.428
2019-06-30 0.292 1.195 -1.429

RCEL Price Target

For more insight on analysts targets of RCEL, see our RCEL price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $40.60 Average Broker Recommendation 1.3 (Strong Buy)

RCEL Stock Price Chart Interactive Chart >

Price chart for RCEL

RCEL Price/Volume Stats

Current price $6.52 52-week high $14.36
Prev. close $6.70 52-week low $4.41
Day low $6.45 Volume 29,400
Day high $6.70 Avg. volume 132,896
50-day MA $5.56 Dividend yield N/A
200-day MA $6.44 Market Cap 163.20M

AVITA Medical, Inc. (RCEL) Company Bio


AVITA Medical, Inc. operates as a medicine company. The Company focuses on the development and commercialization of therapies to address unmet medical needs in patients with burns, chronic wounds, and aesthetics indications. AVITA Medical serves customers worldwide.


RCEL Latest News Stream


Event/Time News Detail
Loading, please wait...

RCEL Latest Social Stream


Loading social stream, please wait...

View Full RCEL Social Stream

Latest RCEL News From Around the Web

Below are the latest news stories about AVITA MEDICAL INC that investors may wish to consider to help them evaluate RCEL as an investment opportunity.

AVITA Medical® to Present at the Piper Sandler 34th Annual Healthcare Conference

VALENCIA, Calif., and MELBOURNE, Australia, Nov. 21, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, announced today that its management team will present at the Piper Sandler 34th Annual Healthcare Conference in New York on Wednesday, November 30, 2022, at 4:30 p.m. Eastern Time. A live audio webcast of the present

Yahoo | November 21, 2022

AVITA Medical® to Host Investor Webinar Briefing

VALENCIA, Calif. and MELBOURNE, Australia, Nov. 16, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, invites shareholders and prospective investors to attend its investor webinar briefing and presentation by Jim Corbett, CEO, and Michael Holder, CFO, on November 23, 2022 at 4:00pm (PST) / November 24, 2022 at 11:00am

Yahoo | November 17, 2022

Wall Street Analysts See a 127% Upside in Avita Medical Inc. (RCEL): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 127.1% in Avita Medical Inc. (RCEL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Yahoo | November 15, 2022

AVITA Medical Third Quarter 2022 Earnings: Beats Expectations

AVITA Medical ( ASX:AVH ) Third Quarter 2022 Results Key Financial Results Revenue: US$9.09m (up 30% from 3Q 2021). Net...

Yahoo | November 13, 2022

AVITA Medical Reports Third Quarter 2022 Financial Results

VALENCIA, Calif. and MELBOURNE, Australia, Nov. 10, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “Company”), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, today reported financial results for the third quarter ended September 30, 2022. Third Quarter Highlights and Recent Updates: Reported commercial revenue, which excludes BARDA revenue, of $9.0 million,

Yahoo | November 10, 2022

Read More 'RCEL' Stories Here

RCEL Price Returns

1-mo 33.33%
3-mo 5.33%
6-mo 16.85%
1-year -52.62%
3-year -84.80%
5-year 21.87%
YTD -45.58%
2021 -35.52%
2020 -59.16%
2019 712.50%
2018 4.67%
2017 -41.82%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8123 seconds.